Eucalyptus

About

Eucalyptus operates a vertically integrated Australian telehealth platform running demographic-focused DTC brands (Pilot, Juniper, Kin, prescription skincare), offering online/text consultations, prescriptions, remote monitoring, and chronic-care programs.

Mission

Eucalyptus sells medical products online across multiple demographic-focused consumer brands, operating through online and text-based consultations that can result in prescribed treatments. Its core brands are Pilot (men’s health), Juniper (women’s weight loss and menopause), Kin (fertility) and Software (prescription skincare); it previously launched and later offloaded a sex-toy brand called Normal. The company emphasizes moving from transactional care toward more comprehensive chronic-disease management, and CEO Tim Doyle says some programs (for example Juniper) include many patient touch points—20 in the first month. Eucalyptus was founded in 2019 by Tim Doyle, Benny Kleist, Alexey Mitko and Charlie Gearside. The business has faced media and medical-community scrutiny over marketing and telehealth prescribing practices, and rivals such as Mosh operate a similar online consultation model. Financially, it has completed multiple funding rounds and most recently raised capital at a reported $520 million valuation. Eucalyptus is a fast-growing Sydney-based online health start-up that provides digital health services. The company has recently attracted significant external capital, raising $60 million in a funding round. Management is evaluating the potential to bring new obesity-management and weight-loss drugs to the Australian market. The raise signals investor confidence in Eucalyptus’s growth trajectory and strategy to expand its clinical offerings. Beyond the new drug plans, the company continues to operate as a digital health platform serving patients online. Eucalyptus operates a vertically integrated telehealth platform that runs four demographic-focused brands, each with its own providers, patient data repository, remote monitoring tools and partner integrations. The company serves more than 200,000 patients and positions itself as a private-pay, direct-to-consumer option in Australia, sometimes charging lower copays than the average $25 doctor visit. Founded in 2019, Eucalyptus has grown rapidly—more than tripling last year—and expects similar growth this year while expanding headcount. The new funding will support product development and the creation of a digital-health portfolio for primary care, with plans to push deeper into chronic care areas such as diabetes, heart conditions and mental health. Over the next year the company intends to introduce new brands around behavioral health, weight management and diabetes to build a hub for ongoing chronic-care touch points. Eucalyptus operates as a consumer brand builder and platform that launches digital products, with two active telehealth brands: Pilot (targeted at young men) and Kin (a subscription contraceptive service for women). The founders—Tim Doyle, Benny Kleist, Alexey Mitko, and Charlie Gearside—moved into telehealth after personal negative healthcare experiences and prior work together at mattress startup Koala. The company is exploring additional consumer verticals and is currently investigating skincare and elderly healthcare with the aim to launch two new brands by the end of the year. Eucalyptus expects to leverage Woolworths' product development and consumer data capabilities to accelerate future brand launches. The business has raised multiple funding rounds to date and counts repeat backer Blackbird among its investors.

Quick Facts